Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

@article{Chertow2012EffectOC,
  title={Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.},
  author={G. Chertow and G. Block and R. Correa-Rotter and T. Dr{\"u}eke and J. Floege and W. Goodman and C. Herzog and Yumi Kubo and G. London and K. Mahaffey and T. Mix and S. Moe and Marie Louise Trotman and D. Wheeler and P. Parfrey},
  journal={The New England journal of medicine},
  year={2012},
  volume={367 26},
  pages={
          2482-94
        }
}
BACKGROUND Disorders of mineral metabolism, including secondary hyperparathyroidism, are thought to contribute to extraskeletal (including vascular) calcification among patients with chronic kidney disease. It has been hypothesized that treatment with the calcimimetic agent cinacalcet might reduce the risk of death or nonfatal cardiovascular events in such patients. METHODS In this clinical trial, we randomly assigned 3883 patients with moderate-to-severe secondary hyperparathyroidism (median… Expand
668 Citations

Paper Mentions

Interventional Clinical Trial
The purpose of this study is to evaluate the effects of cinacalcet (cinacalcet HCl or Sensipar®/Mimpara®) on cardiovascular events and death in chronic kidney disease (CKD… Expand
ConditionsChronic Kidney Disease, Secondary Hyperparathyroidism
InterventionDrug
Cinacalcet for cardiovascular disease in patients undergoing dialysis.
  • G. Tripepi
  • Medicine
  • The New England journal of medicine
  • 2013
  • 9
Cinacalcet does not provide cardiovascular protection in hemodialyzed patients
  • PDF
Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism
  • 15
  • PDF
Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.
  • 42
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.
  • 39
  • PDF
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
  • 971
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.
  • 151
  • PDF
The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.
  • 234
  • PDF
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
  • 2,321
  • PDF
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
  • 1,583
  • PDF
The association between parathyroid hormone and mortality in dialysis patients is modified by wasting
  • C. Drechsler, V. Krane, +5 authors C. Wanner
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2009
  • 37
  • PDF
...
1
2
3
4
5
...